Intra-articular depot formulation principles: Role in the management of postoperative pain and arthritic disorders

Journal of Pharmaceutical Sciences

Volumn 97, Issue 11, 2008, Pages 4622-4654

  Larsen, Claus ^a   Østergaard, Jesper ^a   Larsen, Susan W ^a   Jensen, Henrik ^a   Jacobsen, Stine ^b   Lindegaard, Casper ^b   Andersen, Pia H ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Controlled release delivery; Distribution; Drug delivery system; Formulation; Intra articular; Osteoarthritis; Parenteral depot formulation; Postoperative pain; Rheumatoid arthritis; Targeted drug delivery

Indexed keywords

BETAMETHASONE SODIUM PHOSPHATE; BUPIVACAINE; CEFTAZIDIME; CEFTIOFUR; CHONDROITIN; CORTICOSTEROID; CORTISONE; DICLOFENAC; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETODOLAC; FLURBIPROFEN; GLUCOSAMINE; HYALURONIC ACID; HYDROCORTISONE; IBUPROFEN; INDOMETACIN; LACTOFERRIN; LIDOCAINE; METHOTREXATE; METHYLPREDNISOLONE ACETATE; MORPHINE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PROCAINE; RECOMBINANT PROTEIN; SALICYLIC ACID; TENOXICAM; TIAPROFENIC ACID; TRANSFORMING GROWTH FACTOR BETA1; TRIAMCINOLONE ACETONIDE; ULINASTATIN; UNINDEXED DRUG;

ARTHRITIS; CONTROLLED DRUG RELEASE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG HALF LIFE; DRUG TRANSPORT; NONHUMAN; POSTOPERATIVE PAIN; REVIEW; SYNOVIAL FLUID; SYNOVIUM;

EID: 55749091798     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21346     Document Type: Review

References (327)

1. Caldwell JR. 1996. Intra-articular corticosteroids. Guide to selection and indications for use. Drugs 52:507-514.
2. Hunter JA, Blyth TH. 1999. A risk-benefit assessment of intra-articular corticosteroids in rheumatic disorders. Drug Saf 21:353-365.
3. Bellamy N, Campbell J, Robinson V, Gee T, Bourne R, Wells G. 2006. Intraarticular corticosteroid for treatment of osteoarthritis of the knee. Cochrane Database Syst Rev 2:CD005328.
4. Buckwalter JA, Martin JA. 2006. Osteoarthritis. Adv Drug Deliv Rev 58:150-167.
5. Baker CL, Ferguson CM. 2005. Future treatment of osteoarthritis. Orthopedics 28:S227-S234.
6. Evans CH. 2005. Novel biological approaches to the intra-articular treatment of osteoarthritis. BioDrugs 19:355-362.
7. Wieland HA, Michaelis M, Kirschbaum BJ, Rudolphi KA. 2005. Osteoarthritis. An untreatable disease. Nat Rev Drug Discov 4:331-344.
8. Abramson S. 2006. Drug delivery in degenerative joint disease: Where we are and where to go? Adv Drug Deliv Rev 58:125-127.
9. Tomlinson E. 1987. Theory and practice of site-specific drug delivery. Adv Drug Deliv Rev 1:87-198.
10. Gardner E. 1972. The structure and function of joints. 8 edition. Philadelphia: Lea and Febiger. pp. 32-50.
11. Agarwal SK, Brenner MB. 2006. Role of adhesion molecules in synovial inflammation. Curr Opin Rheumatol 18:268-276.
12. Pap T, M-Ladner U, Gay RE, Gay S. 2007. Fibroblast biology. Role of synovial fibroblasts in the pathogenesis of rheumatoid arthritis. Arthritis Res 2:361-367.
13. Stanczyk J, Ospelt C, Gay RE, Gay S. 2006. Synovial cell activation. Curr Opin Rheumatol 18:262-267.
14. Szekanecz Z, Szucs G, Szanto S, Koch AE. 2006. Chemokines in rheumatic diseases. Curr Drug Targets 7:91-102.
15. Evans CH, Gouze E, Gouze JN, Robbins PD, Ghivizzani SC. 2006. Gene therapeutic approaches-transfer in vivo. Adv Drug Deliv Rev 58:243-258.
16. Jessar RA. 1972. The study of synovial fluid. 8 edition. Philadelphia: Lea and Febiger. pp. 67-81.
17. Tercic D, Bozic B. 2001. The basis of the synovial fluid analysis. Clin Chem Lab Med 39:1221-1226.
18. Carney SL, Muir H. 1988. The structure and function of cartilage proteoglycans. Physiol Rev 68:858-910.
19. Aigner T, Stove J. 2003. Collagens - Major component of the physiological cartilage matrix, major target of cartilage degeneration, major tool in cartilage repair. Adv Drug Deliv Rev 55:1569-1593.
20. Hardingham TE, Fosang AJ. 1992. Proteoglycans - Many forms and many functions. FASEB J 6:861-870.
21. Goldring MB. 2006. Update on the biology of the chondrocyte and new approaches to treating cartilage diseases. Best Pract Res Clin Rheumatol 20:1003-1025.
22. Vinatier C, Guicheux J, Daculsi G, Layrolle P, Weiss P. 2006. Cartilage and bone tissue engineering using hydrogels. Biomed Mater Eng 16:S107-S113.
23. Nesic D, Whiteside R, Brittberg M, Wendt D, Martin I, Mainil-Varlet P. 2006. Cartilage tissue engineering for degenerative joint disease. Adv Drug Deliv Rev 58:300-322.
24. Lee S-H, Shin H. 2007. Matrices and scaffolds for delivery of bioactive molecules in bone and cartilage tissue engineering. Adv Drug Deliv Rev 59:339-359.
25. Brown AK, Christo PJ, Wu CL. 2004. Strategies for postoperative pain management. Best Pract Res Clin Anaesthesiol 18:703-714.
26. Reuben SS, Sklar J. 2000. Current concepts review. Pain management in patients who undergo outpatient arthroscopic surgery of the knee. J Bone Joint Surg 82-A:1754-1766.
27. Rasmussen S, Larsen AS, Thomsen ST, Kehlet H. 1998. Intra-articular glucocorticoid, bupivacaine and morphine reduces pain, inflammatory response and convalescence after arthroscopic meniscectomy. Pain 78:131-134.
28. Gupta A. 2003. Update on intra-articular analgesia. Techniq Reg Anesth Pain Man 7:155-160.
29. Rømsing J, Møiniche S, Østergaard D, Dahl JB. 2000. Local infiltration with NSAIDs for postoperative analgesia: Evidence for a peripheral analgesic action. Acta Anaesthesiol Scand 44:672-683.
30. Møiniche S, Mikkelsen S, Wetterslev J, Dahl JB. 1999. A systematic review of intra-articular local anesthesia for postoperative pain relief after arthroscopic knee surgery. Reg Anesth Pain Med 24:430-437.
31. Kalso E, Smith L, McQuay HJ, Moore RA. 2002. No pain, no gain: Clinical exellence and scientific rigour - Lessons learned from IA morphine. Pain 98:269-275.
32. Gupta A, Bodin L, Holmström B, Berggren L. 2001. A systematic review of the peripheral analgesic effects of intraarticular morphine. Anesth Analg 93:761-770.
33. Kehlet H, Dahl JB. 1993. The value of multimodal or balanced analgesia in postoperative pain treatment. Anesth Analg 77:1048-1056.
34. Kehlet H, Werner M, Perkins F. 1999. Balanced analgesia - What is it and what are its advantages in postoperative pain? Drugs 58:793-797.
35. Elhakim M, Nafie M, Eid A, Hassin M. 1999. Combination of intra-articular tenoxican, lidocaine and pethidine for outpatient knee arthroscopy. Acta Anaesthesiol Scand 43:803-808.
36. Talu GK, Özyalcm S, Koltka K, Ertürk E, Akmer Ö, Asik M, Pembeci K. 2002. Comparison of efficacy of intraarticular application of tenoxicam, bupivacaine and tenoxicam: Bupivacaine combination in arthroscopic knee surgery. Knee Surg Sports Traumatol Arthrosc 10:355-360.
37. Uysalei A, Kecik Y, Kirdemir P, Sayin M, Binnet M. 1995. Comparison of intraarticular bupivacaine with the addition of morphine or fentanyl for analgesia after arthroscopic surgery. Arthroscopy 11:660-663.
38. Reuben SS, Connelly NR. 1995. Postoperative analgesia for outpatient arthroscopic knee surgery with intraarticular bupivacaine and ketorolac. Anesth Analg 80:1154-1157.
39. Rasmussen S, Lorentzen JS, Larsen AS, Thomsen ST, Kehlet H. 2002. Combined intra-articular glucocorticoid, bupivacaine and morphine reduces pain and convalescence after diagnostic knee arthroscopy. Acta Orthop Scand 73:175-178.
40. Rasmussen S, Kehlet H. 2000. Intraarticular glucocorticoid, morphine and bupivacaine reduces pain and convalescence after arthroscopic ankle surgery: A randomized study of 36 patients. Acta Orthop Scand 71:301-304.
41. Kizilkaya M, Yildirim OS, Dogan N, Kursad H, Okur A. 2004. Analgesic effects of intraarticular sufentanil and sufentanil plus methylprednisolone after arthroscopic knee surgery. Anesth Analg 98: 1062-1065.
42. Buerkle H, Huge V, Wolfgart M, Steinbeck J, Mertes N, Van Aken H, Prien T. 2000. Intraarticular clonidine analgesia after knee arthroscopy. Eur J Anaesthesiol 17:295-299.
43. Reuben SS, Connelly NR. 1999. Postoperative analgesia for outpatient arthroscopic knee surgery with intraarticular clonidine. Anesth Analg 88:729-733.
44. Sandell LJ, Aigner T. 2001. Articular cartilage and changes in arthritis. An introduction: Cell biology of osteoaerthritis. Arthritis Res 3:107-113.
45. McIlwraith CW. 2005. Use of synovial fluid and serum biomarkers in equine bone and joint disease: A review. Equine Vet J 27:473-482.
46. Burrage PS, Mix KS, Brincherhoff CE. 2006. Matrix metalloproteinases: Role in arthritis. Front Biosci 11:529-543.
47. Abramson SB, Attur M, Yazici Y. 2006. Prospects for disease modification in osteoarthritis. Nat Clin Pract Rheumatol 2:304-312.
48. Cooper NJ. 2000. Economic burden of rheumatoid arthrtis: A systematic review. Rheumatology (Oxford) 39:28-33.
49. Elders MJ. 2000. The increasing impact of arthritis on public health. J Rheumatol 27:6-8.
50. Reginster JY, Khaltaev NG. 2002. Introduction and WHO perspective on the global burden of musculoskeletal conditions. Rheumatology (Oxford) 41:1-2.
51. Choy EH, Panayi GS. 2001. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344:907-916.
52. Cannella AC, O'Dell JR. 2006. Early rheumatoid arthritis - Pitfalls in diagnosis and review of recent clinical trials. Drugs 66:1319-1337.
53. Steinmeyer J, Konttinen YT. 2006. Oral treatment options for degenerative joint disease-presence and future. Adv Drug Deliv Rev 58:168-211.
54. Haagsma CJ, Russel FG, Vree TB, Van Riel PL, Van de Putte LB. 1996. Combination of methotrexate and sulphasalazine in patients with rheumatoid arthritis: Pharmacokinetic analysis and relationship to clinical response. Br J Clin Pharmacol 42: 195-200.
55. Proudman SM, Conaghan PG, Richardson C, Griffiths B, Green MJ, McGonagle D, Wakefield RJ, Reece RJ, Miles S, Adebajo A, Gough A, Helliwell P, Martin M, Huston G, Pease C, Veale DJ, Isaacs J, van der Heijde DM, Emery P. 2000. Treatment of poor-prognosis early rheumatoid arthritis. A randomized study of treatment with methotrexate, cyclosporin A, and intraarticular corticosteroids compared with sulfasalazine alone. Arthritis Rheum 43:1809-1819.
56. Wilke WS, Mackenzie AH. 1986. Methotrexate therapy in rheumatoid arthritis current status. Drugs 32:103-113.
57. Mullan RH, Bresnihan B. 2003. Disease-modifying anti-rheumatic drug therapy and structural damage in early rheumatoid arthritis. Clin Exp Rheumatol 21:S158-S164.
58. Smith RJ. 2005. Therapies for rheumatoid arthritis: Hope springs eternal. Drug Discov Today 10:1598-1606.
59. Gartlehner G, Hansen RA, Jonas BL, Thieda P, Lohr KN. 2006. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: A systematic review and metaanalysis. J Rheumatol 33:2398-2408.
60. Fleurence R, Spackman E. 2006. Cost-effectiveness of biologic agents for the treatment of autoimmune disorders: Structured review of the literature. J Rheumatol 33:2124-2131.
61. Christodoulou C, Choy EH. 2006. Joint inflammation and cytokine inhibition in rheumatoid arthritis. Clin Exp Med 6:13-19.
62. Aigner T, Sachse A, Gebhard PM, Roach HI. 2006. Osteoarthritis: Pathobiology-targets and ways for therapeutic intervention. Adv Drug Deliv Rev 58:128-149.
63. Pelletier JP, Martel-Pelletier J, Abramson SB. 2001. Osteoarthritis, an inflammatory disease - Potential implication for the selection of new therapeutic targets. Arthritis Rheum 44:1237-1247.
64. Watterson JR, Esdaile JM. 2000. Viscosupplementation: Therapeutic mechanisms and clinical potential in osteoarthritis of the knee. J Am Acad Orthop Surg 8:277-284.
65. Uthman I, Raynauld JP, Haraoui B. 2003. Intraarticular therapy in osteoarthritis. Postgrad Med J 79:449-453.
66. Gerwin N, Hops C, Lucke A. 2006. Intraarticular drug delivery in osteoarthritis. Adv Drug Deliv Rev 58:226-242.
67. Gossec L, Dougados M. 2006. Do intra-articular therapies work and who will benefit most? Best Pract Res Clin Rheumatol 20:131-144.
68. Curtis CL, Harwood JL, Dent CM, Caterson B. 2004. Biological basis for the benefit of nutraceutical supplementation in arthritis. Drug Discov Today 9:165-172.
69. Hogenmiller MS, Lozada CJ. 2006. An update on osteoarthritis therapeutics. Curr Opin Rheumatol 18:256-260.
70. Tremoulet AH, Albani S. 2006. Novel therapies for rheumatoid arthritis. Expert Opin Investig Drugs 15:1427-1441.
71. Goldring MB. 2001. Anticytokine therapy for osteoarthritis. Expert Opin Biol Ther 1:817-829.
72. Abramson SB, Yazici Y. 2006. Biologics in development for rheumatoid arthritis: Relevance to osteoarthritis. Adv Drug Deliv Rev 58:212-225.
73. Chevalier X, Giraudeau B, Conrozier T, Marliere J, Kiefer P, Goupille P. 2005. Safety study of intraarticular injection of interleukin 1 receptor antagonist in patients with painful knee osteoarthritis: A multicenter study. J Rheumatol 32:1317-1323.
74. Cornelis S, Kersse K, Festjens N, Lamkanfi M, Vandenabeele P. 2007. Inflammatory caspases: Targets for novel therapies. Curr Pharm Des 13:365-383.
75. Valko M, Leibfritz D, Moncol J, Cronin MTD, Mazur M, Telser J. 2007. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 39:44-84.
76. Henrotin Y, Kurz B, Aigner T. 2005. Oxygen and reactive oxygen species in cartilage degradation: Friends or foes? Osteoarthr Cartil 13:643-654.
77. Vasiljeva O, Reinheckel T, Peters C, Turk D, Turk K, Turk B. 2007. Emerging roles of cysteine cathepsins in disease and their potential as drug targets. Curr Pharm Des 13:385-401.
78. Yasuda Y, Kaleta J, Bromme D. 2005. The role of cathepsins in osteoporosis and arthritis: Rationale for the design of new therapeutics. Adv Drug Deliv Rev 57:973-993.
79. Konttinen YT, Mandelin J, Li TF, Salo J, Lassus J, Liljestrom M, Hukkanen M, Takagi M, Virtanen I, Santavirta S. 2002. Acidic cysteine endoproteinase cathepsin K in the degeneration of the superficial articular hyaline cartilage in osteoarthritis. Arthritis Rheum 46:953-960.
80. Nakano S, Ikata T, Kinoshita I, Kanematsu J, Yasuoka S. 1999. Characteristics of the protease activity in synovial fluid from patients with rheumatoid arthritis and osteoarthritis. Clin Exp Rheumatol 17:161-170.
81. Mantle D, Falkous G, Walker D. 1999. Quantification of protease activities in synovial fluid from rheumatoid and osteoarthritis cases: Comparison with antioxidant and free radical damage markers. Clin Chim Acta 284:45-58.
82. Holland TA, Mikos AG. 2003. Advances in drug delivery for articular cartilage. J Control Release 86:1-14.
83. Schmidt MB, Chen EH, Lynch SE. 2006. A review of the effects of insulin-like growth factor and platelet derived growth factor on in vivo cartilage healing and repair. Osteoarthr Cartil 14:403-412.
84. Issack PS, DiCesare PE. 2003. Recent advances toward the clinical application of bone morphogenetic proteins in bone and cartilage repair. Am J Orthop 32:429-436.
85. Vanderslice P, Woodside DG. 2006. Integrin antagonists as therapeutics for inflammatory diseases. Expert Opin Investig Drugs 15:1235-1255.
86. Ludwig RJ, Alban S, Boehncke WH. 2006. Structural requirements of heparin and related molecules to exert a multitude of anti-inflammatory activities. Mini Rev Med Chem 6:1009-1023.
87. Paul AT, Gohil VM, Bhutani KK. 2006. Modulating TNF-alpha signaling with natural products. Drug Discov Today 11:725-732.
88. Reuning U, Magdolen V, Wilhelm O, Fischer K, Lutz V, Graeff H, Schmitt M. 1998. Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis (review). Int J Oncol 13:893-906.
89. Curran S, Murray GI. 2000. Matrix metalloproteinases: Molecular aspects of their roles in tumour invasion and metastasis. Eur J Cancer 36:1621-1630.
90. Overall CM, Lopez-Otin C. 2002. Strategies for MMP inhibition in cancer: Innovation for the post-trial era. Nature Rev Cancer 2:657-672.
91. Thorpe PE. 2004. Vascular targeting agents as cancer therapeutics. Clin Cancer Res 10:415-427.
92. Mizejewski GJ. 1999. Role of integrins in cancer: Survey of expression patterns. Proc Soc Exp Biol Med 222:124-138.
93. de Groot V. 2007. Targeting: Cancer - Small molecules. In: Stella VJ, Borchardt RT, Hageman MJ, Oliyai R, Maag H, Tilley JW, editors. Prodrugs: Challenges and rewards. New York: Springer. pp. 447-506.
94. Levick JR. 1995. Microvascular architecture and exchange in synovial joints. Microcirculation 2:217-233.
95. Levick JR, Smaje LH. 1987. An analysis of the permeability of a fenestra. Microvasc Res 33:233-256.
96. Day RO, McLachlan AJ, Graham GG, Williams KM. 1999. Pharmacokinetics of nonsteroidal antiinflammatory drugs in synovial fluid. Clin Pharmacokinet 36:191-210.
97. Simkin PA, Pizzorno JE. 1979. Synovial permeability in rheumatoid arthitis. Arthritis Rheum 22:689-696.
98. Simkin PA. 2005. Synovial physiology. In: Koopman WJ, Moreland LW, editors. Arthiritis and allied conditions: A textbook of rheumatology. 15 edition. Philadelphia: Lippincott Williams and Wilkins. pp. 175-187.
99. Levick JR. 1981. Permeability of rheumatoid and normal human synovium to specific plasma proteins. Arthritis Rheum 24:1550-1560.
100. Wallis WJ, Simkin PA. 1983. Antirheumatic drug concentrations in human synovial fluid and synovial tissue. Observations on extravascular pharmacokinetics. Clin Pharmacokinet 8:496-522.
101. Netter P, Bannwarth B, Royer-Morrot M-J. 1989. Recent findings on the pharmacokinetics of nonsteroidal anti-inflammatory drug in the synovial fluid. Clin Pharmacokinet 17:145-162.
102. Simkin PA, Nilson KL. 1981. Trans-synovial exchange of large and small molecules. Clin Rheum Dis 7:99-129.
103. Owen SG, Francis HW, Roberts MS. 1994. Disappearance kinetics of solutes from synovial fluid after intra-articular injection. Br J Clin Pharmacol 38:349-355.
104. Wigginton SM, Chu BC, Weisman MH, Howell SB. 1980. Methotrexate pharmacokinetics after intraarticular injection in patients with rheumatoid arthritis. Arthritis Rheum 23:119-122.
105. Ohzawa N, Takahashi Y, Ogihara T, Nakai Y, Ishiguro J. 1997. Metabolic fate of ulinastatin (2); pharmacokinetics in rabbits following intraarticular administration. Biol Pharm Bull 20:732-738.
106. Phelps P, Steele AD, McCarthy DJ. 1972. Significance of xenon-133 clearance rate from canine and human joints. Arthritis Rheum 15:360-370.
107. 133Xe) disappearance rates from the synovial cavity of the human knee joint in normal and arthritic subjects. Ann Rheum Dis 27:163-166.
108. Mills ML, Rush BR, St Jean G, Gaughan EM, Mosier D, Gibson E, Freeman L. 2000. Determination of synovial fluid and serum concentrations, and morphologic effects of intraarticular ceftiofur sodium in horses. Vet Surg 29:398-406.
109. 14-cortisol in rheumatoid arthritis. Arthritis Rheum 10:352-356.
110. Harris R, Millard JB. 1956. Clearance of radioactive sodium from the knee joint. Clin Sci 15:9-15.
111. Poli A, Scott D, Bertin K, Miserocchi G, Mason RM, Levick JR. 2001. Influence of actin cytoskeleton on intra-articular and interstitial fluid pressures in synovial joints. Microvasc Res 62:293-305.
112. Simkin PA, Pizzorno JE. 1974. Transsynovial exchange of small molecules in normal human subjects. J Appl Physiol 36:581-587.
113. Simkin PA, Wu MP, Foster DM. 1993. Articular pharmacokinetics of protein-bound antirheumatic agents. Clin Pharmacokinet 25:342-350.
114. Brown DL, Cooper AG, Bluestone R. 1969. Exchange of IgM and albumin between plasma and synovial fluid in rheumatoid arthritis. Ann Rheum Dis 29:644-651.
115. Wallis WJ, Simkin PA, Nelp WB. 1987. Protein traffic in human synovial effusions. Arthritis Rheum 30:57-63.
116. Weinberger A, Simkin PA. 1989. Plasma proteins in synovial fluids of normal human joints. Semin Arthritis Rheum 19:66-76.
117. Simkin PA, Bassett JE, Koh E-M. 1995. Synovial perfusion in the human knee: A methodologic analysis. Semin Arthritis Rheum 25:56-66.
118. Bauer W, Short CL, Bennett GA. 1933. The manner of removal of proteins from normal joints. J Exp Med 57:419-433.
119. Simkin PA, Benedict RS. 1990. Iodide and albumin kinetics in normal canine wrists and knees. Arthritis Rheum 33:73-79.
120. Rodnan GP, MacLachlan MJ. 1960. The absorption of serum albumin and gamma globulin from the joint of man and rabbit. Arthritis Rheum 3:152-157.
121. van Lent PL, van den BL, Grutters GJ, van den Berg WB. 1989. Fate of antigen after intravenous and intraarticular injection into mice. Role of molecular weight and charge. J Rheumatol 16:1295-1303.
122. Page-Thomas DP, Bard D, King B, Dingle JT. 1987. Clearance of proteoglycan from joint cavities. Ann Rheum Dis 46:934-937.
123. Coleman PJ, Scott D, Ray J, Mason RM, Levick JR. 1997. Hyaluronan secretion into the synovial cavity of rabbit knees and comparison with albumin turnover. J Physiol 503:645-656.
124. Brown TJ, Laurent UBG, Fraser JFE. 1991. Turnover of hyaluronan in synovial joints: Elimination of labelled hyaluronan from the knee joint of the rabbit. Exp Physiol 76:125-134.
125. Maroudas A, Bullough P, Swanson SAV, Freeman MAR. 1968. The permeability of articular cartilage. J Bone Joint Surg Br 50B:166-177.
126. Maroudas A. 1970. Distribution and diffusion of solutes in articular cartilage. Biophys J 10:365-379.
127. Gonsalves M, Barker AL, Macpherson JV, Unwin PR, O'Hare D, Winlove CP. 2000. Scanning electrochemical microscopy as a local probe of oxygen permeability in cartilage. Biophys J 78:1578-1588.
128. Gonsalves M, Macpherson JV, O'Hare D, Winlove CP, Unwin PR. 2000. High resolution imaging of the distribution and permeability of methyl viologen dication in bovine articular cartilage using scanning electrochemical microscopy. Biochim Biophys Acta 1524:66-74.
129. Leddy HA, Guilak F. 2003. Site-specific molecular diffusion in articular cartilage measured using fluorescence recovery after photobleaching. Ann Biomed Eng 31:753-760.
130. Stolz M, Raiteri R, Daniels AU, VanLandingham MR, Baschong W, Aebi U. 2004. Dynamic elastic modulus of porcine articular cartilage determined at two different levels of tissue organization by indentation-type atomic force microscopy. Biophys J 86:3269-3283.
131. Evans RC, Quinn TM. 2006. Dynamic compression augments interstitial transport of a glucose-like solute in articular cartilage. Biophys J 91:1541-1547.
132. Evans RC, Quinn TM. 2006. Solute convection in dynamically compressed cartilage. J Biomech 39:1048-1055.
133. Quinn TM, Morel V, Meister JJ. 2001. Static compression of articular cartilage can reduce solute diffusivity and partitioning: Implications for the chondrocyte biological response. J Biomech 34:1463-1469.
134. Quinn TM, Kocian P, Meister JJ. 2000. Static compression is associated with decreased diffusivity of dextrans in cartilage explants. Arch Biochem Biophys 384:327-334.
135. Maroudas A. 1968. Physicochemical properties of cartilage in light of ion exchange theory. Biophys J 8:575-595.
136. Nimer E, Schneiderman R, Maroudas A. 2003. Diffusion and partition of solutes in cartilage under static load. Biophys Chem 106:125-146.
137. Maroudas A. 1980. Physical chemistry of articular cartilage and the intervertebral disc. In: Sokoloff L, editor. The joints and synovial fluid. New York: Academic Press. pp. 239-291.
138. Olsen GD, Chan EM, Riker WK. 1975. Binding of D-tubocurarine di[methyl-C-14] ether iodide and other amines to cartilage, chondroitin sulfate and human plasma-proteins. J Pharmacol Exp Ther 195:242-250.
139. Maurizis JC, Ollier M, Nicolas C, Madelmont JC, Garrigue H, Veyre A. 1992. In vitro binding of oxime acetylcholinesterase reactivators to proteoglycans synthesized by cultured chondrocytes and fibroblasts. Biochem Pharmacol 44:1927-1933.
140. Bannwarth B, Netter P, Lapicque F, Mainard D, Fener P, Gillet P, Gaucher A. 1991. Tenoxicam concentrations in synovium and joint cartilage in humans. Agents Actions 32:295-298.
141. Giraud I, Rapp M, Maurizis JC, Madelmont JC. 2002. Synthesis and in vitro evaluation of quaternary ammonium derivatives of chlorambucil and melphalan, anticancer drugs designed for the chemotherapy of chondrosarcoma. J Med Chem 45:2116-2119.
142. Giraud I, Rapp M, Maurizis JC, Madelmont JC. 2000. Application to a cartilage targeting strategy: Synthesis and in vivo biodistribution of C-14-labeled quaternary ammonium-glucosamine conjugates. Bioconjug Chem 11:212-218.
143. Maurizis JC, Rapp M, Nicolas C, Ollier M, Verny M, Madelmont JC. 2000. Disposition in rats of N-pyridinium-propyl-cyclam, N-triethylammonium-propyl- cyclam, and N-[Triethylammonium]-3-propyl-[15]ane-N5, potential cartilage imaging agents. Drug Metab Dispos 28:418-422.
144. Nicolas C, Verny M, Giraud I, Ollier M, Rapp M, Maurizis JC, Madelmont JC. 1999. New quaternary ammonium oxicam derivatives targeted toward cartilage: Synthesis, pharmacokinetic studies, and antiinflammatory potency. J Med Chem 42:5235-5240.
145. Rapp M, Giraud I, Maurizis JC, Madelmont JC. 2003. Synthesis and pharmacokinetic profile of a quaternary ammonium derivative of chlorambucil, a potential anticancer drug for the chemotherapy of chondrosarcoma. Bioorg Med Chem 11:5007-5012.
146. Rapp M, Giraud I, Maurizis JC, Galmier MJ, Madelmont JC. 2003. Synthesis and in vivo biodisposition of [C-14]-quaternary ammonium-melphalan conjugate, a potential cartilage-targeted alkylating drug. Bioconjug Chem 14:500-506.
147. Vidal A, Sabatini M, Rolland-Valognes G, Renard P, Madelmont JC, Mounetou E. 2007. Synthesis and in vitro evaluation of targeted tetracycline derivatives: Effects on inhibition of matrix metalloproteinases. Bioorg Med Chem 15:2368-2374.
148. Rowland M, Tozer TN. 1989. Clinical pharmacokinetics. Concepts and applications. 2nd edition. Philadelphia-London: Lea and Febiger.
149. Harris R, Millard JB, Banerjee SK. 1958. Radiosodium clearance from the knee joint in rheumatoid arthritis. Ann Rheum Dis 17:189-195.
150. Scholer JF, Lee PR, Polley HF. 1959. The absorption of heavy water and radioactive sodium from the knee joint of normal persons and patients with rheumatoid arthritis. Arthritis Rheum 2:426-432.
151. Peterson RE, Black RL, Bunim JJ. 1959. Disposition of intra-articularly injected cortisone and hydrocortisone. Arthritis Rheum 2:433-439.
152. Moritz F, Distler O, Ospelt C, Gay RE, Gay S. 2006. Technology insight: Gene transfer and the design of novel treatments for rheumatoid arthritis. Nat Clin Pract Rheumatol 2:153-162.
153. Evans CH, Ghivizzani SC, Robbins PD. 2006. Gene therapy for arthritis - What next? Arthritis Rheum 54:1714-1729.
154. Keller M. 2005. Lipidic carriers of RNA/DNA oligonucleotides and polynucleotides: What a difference a formulation makes. J Control Release 103:537-540.
155. Evans CH, Gouze JN, Gouze E, Robbins PD, Ghivizzani SC. 2004. Osteoarthritis gene therapy. Gene Ther 11:379-389.
156. Gelse K, Schneider H. 2006. Ex vivo gene therapy approaches to cartilage repair. Adv Drug Deliv Rev 58:259-284.
157. Matheson AJ, Figgitt DP. 2001. Rofecoxib - A review of its use in the management of osteoarthritis, acute pain and rheumatoid arthritis. Drugs 61:833-865.
158. van de Loo F, de Hooge A, Smeets RL, Bakker AC, Bennink AC, Arntz OJ, Joosten LAB, van Beuningen HM, van der Kraan PK, Varley AW, van den Berg WB. 2004. An inflammation-inducible adenoviral expression system for local treatment of the arthritic joint. Gene Ther 11:581-590.
159. Schatteman L, Gyselbrecht L, De Clercq L, Mielants H. 2006. Treatment of refractory inflammatory monoarthritis in ankylosing spondylitis by intraarticular injection of infliximab. J Rheumatol 33:82-85.
160. Conti F, Priori R, Chimenti MS, Coari G, Annovazzi A, Valesini G, Signore A. 2005. Successful treatment with intraarticular infliximab for resistant knee monarthritis in a patient with spondylarthropathy - A role for scintigraphy with Tc-99m-infliximab. Arthritis Rheum 52:1224-1226.
161. Veale DJ, Reece RJ, Parsons W, Radjenovic A, O'Connor PJ, Orgles CS, Berry E, Ridgway JP, Mason U, Boylston AW, Gibbon W, Emery P. 1999. Intra-articular primatised anti-C D4: Efficacy in resistant rheumatoid knees. A study of combined arthroscopy, magnetic resonance imaging, and histology. Ann Rheum Dis 58:342-349.
162. Holland T, Jones R, Basford A, Child T, Smith A. 2000. An intra-articular method for assessing topical application to a synovial joint. Lab Anim 34:298-300.
163. Wind WM, Smolinski RJ. 2004. Reliability of common knee injection sites with low-volume injections. J Arthroplasty 19:858-861.
164. Ingpen ML. 1995. Joint injections: Intra-articular and periarticular techniques. Modern Med 38:20-27.
165. Shi Y, Li LC. 2005. Current advances in sustained-release systems for parenteral drug delivery. Expert Opin Drug Deliv 2:1039-1058.
166. Torchilin VP. 2005. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 4:145-160.
167. Metselaar JM, Storm G. 2005. Liposomes in the treatment of inflammatory disorders. Expert Opin Drug Deliv 2:465-476.
168. Moghimi SM, Hamad I, Bunger R, Andresen TL, Jorgensen K, Hunter AC, Baranji L, Rosivall L, Szebeni J. 2006. Activation of the human complement system by cholesterol-rich and pegylated liposomes - Modulation of cholesterol-rich liposome-mediated complement activation by elevated serum LDL and HDL levels. J Liposome Res 16:167-174.
169. Moghimi SM, Hamad I, Andresen TL, Jorgensen K, Szebeni J. 2006. Methylation of the phosphate oxygen moiety of phospholipid-methoxy(polyethylene glycol) conjugate prevents PEGylated liposome-mediated complement activation and anaphylatoxin production. FASEB J 20:2591-2593.
170. Sharma A, Sharma US. 1997. Liposomes in drug delivery: Progress and limitations. Int J Pharm 154:123-140.
171. Phillips NC, Thomas DP, Knight CG, Dingle JT. 1979. Liposome-incorporated corticosteroids. II. Therapeutic activity in experimental arthritis. Ann Rheum Dis 38:553-557.
172. Lopez-Garcia F, Vazquez-Auton JM, Gil F, Latoore R, Moreno F, Villalain J, Gomez-Fernandez JC. 1993. Intra-articular therapy of experimental arthritis with a derivative of triamcinolone acetonide incorporated in liposomes. J Pharm Pharmacol 45:576-578.
173. Dingle JT, Gordon JL, Hazleman BL, Knight CG, Page Thomas DP, Phillips NC, Shaw IH, Fildes FJ, Oliver JE, Jones G, Turner EH, Lowe JS. 1978. Novel treatment for joint inflammation. Nature 271:372-373.
174. de Silva M, Hazleman BL, Thomas DP, Wraight P. 1979. Liposomes in arthritis: A new approach. Lancet 1:1320-1322.
175. Bonanomi MH, Velvart M, Weder HG. 1987. Fate of different kinds of liposomes containing dexamethasone palmitate after intra-articular injection into rabbit joints. J Microencapsul 4:189-200.
176. Bonanomi MH, Velvart M, Stimpel M, Roos KM, Fehr K, Weder HG. 1987. Studies of pharmacokinetics and therapeutic effects of glucocorticoids entrapped in liposomes after intraarticular application in healthy rabbits and in rabbits with antigen-induced arthritis. Rheumatol Int 7:203-212.
177. Shaw IH, Knight CG, Dingle JT. 1976. Liposomal retention of a modified anti-inflammatory steroid. Biochem J 158:473-476.
178. Turker S, Erdogan S, Ozer AY, Ergun EL, Tuncel M, Bilgili H, Deveci S. 2005. Scintigraphic imaging of radiolabelled drug delivery systems in rabbits with arthritis. Int J Pharm 296:34-43.
179. Hou SM, Yu HY. 1997. Comparison of systemic absorption of aqueous and liposomal lidocaine following intra-articular injection in rabbits. J Formos Med Assoc 96:141-143.
180. Foong WC, Green KL. 1988. Retention and distribution of liposome-entrapped [3H]methotrexate injected into normal or arthritic rabbit joints. J Pharm Pharmacol 40:464-468.
181. Mantripragada S. 2002. A lipid based depot (Depo-Foam((R)) technology) for sustained release drug delivery. Prog Lipid Res 41:392-406.
182. Sinha VR, Trehan A. 2005. Biodegradable microspheres for parenteral delivery. CRC Crit Rev Ther Drug Carrier Syst 22:535-602.
183. Jiang WL, Gupta RK, Deshpande MC, Schwendeman SP. 2005. Biodegradable poly(lactic-coglycolic acid) microparticles for injectable delivery of vaccine antigens. Adv Drug Deliv Rev 57:391-410.
184. Freitas S, Merkle HP, Gander B. 2005. Microencapsulation by solvent extraction/evaporation: Reviewing the state of the art of microsphere preparation process technology. J Control Release 102:313-332.
185. Jain JP, Modi S, Domb AJ, Kumar N. 2005. Role of polyanhydrides as localized drug carriers. J Control Release 103:541-563.
186. Kumar N, Langer RS, Domb AJ. 2002. Polyanhydrides: An overview. Adv Drug Deliv Rev 54:889-910.
187. Heller J, Barr J, Ng SY, Abdellauoi KS, Gurny R. 2002. Poly(ortho esters): Synthesis, characterization, properties and uses. Adv Drug Deliv Rev 54:1015-1039.
188. Sinha VR, Bansal K, Kaushik R, Kumria R, Trehan A. 2004. Poly-epsilon-caprolactone microspheres and nanospheres: An overview. Int J Pharm 278:1-23.
189. Patil GV. 2003. Biopolymer albumin for diagnosis and in drug delivery. Drug Dev Res 58:219-247.
190. Kumar MNVR, Muzzarelli RAA, Muzzarelli C, Sashiwa H, Domb AJ. 2004. Chitosan chemistry and pharmaceutical perspectives. Chem Rev 104:6017-6084.
191. Sung KC, Han RY, Hu OYP, Hsu LR. 1998. Controlled release of nalbuphine prodrugs from biodegradable polymeric matrices: Influence of prodrug hydrophilicity and polymer composition. Int J Pharm 172:17-25.
192. Liu C, Desai KGH, Tang X, Chen X. 2006. Drug release kinetics of spray-dried chitosan microspheres. Drying Technol 24:769-776.
193. von Burkersroda F, Schedl L, Gopferich A. 2002. Why degradable polymers undergo surface erosion or bulk erosion. Biomaterials 23:4221-4231.
194. Schliecker G, Schmidt C, Fuchs S, Wombacher R, Kissel T. 2003. Hydrolytic degradation of poly (lactide-co-glycolide) films: Effect of oligomers on degradation rate and crystallinity. Int J Pharm 266:39-49.
195. Monkkonen J, Liukkonen J, Taskinen M, Heath TD, Urtti A. 1995. Studies on liposome formulations for intraarticular delivery of clodronate. J Control Release 35:145-154.
196. Brown KE, Leong K, Huang CH, Dalal R, Green GD, Haimes HB, Jimenez PA, Bathon J. 1998. Gelatin/chondroitin 6-sulfate microspheres for the delivery of therapeutic proteins to the joint. Arthritis Rheum 41:2185-2195.
197. Berger RG, Yount WJ. 1990. Immediate "steroid flare" from intraarticular triamcinolone hexacetonide injection: Case report and review of the literature. Arthritis Rheum 33:1284-1286.
198. Kahn CB, Hollander JL, Schumacher HR. 1970. Corticosteroid crystals in synovial fluid. JAMA 211:807-809.
199. Akers MJ, Fites AL, Robinson RL. 1987. Formulation design and development of parenteral suspensions. J Parenter Sci Technol 41:88-96.
200. Hiestand EN. 1964. Theory of coarse suspension formulation. J Pharm Sci 53:1-18.
201. Betre H, Liu W, Zalutsky MR, Chilkoti A, Kraus VB, Setton LA. 2006. A thermally responsive biopolymer for intra-articular drug delivery. J Control Release 115:175-182.
202. Zentner GM, Rathi R, Shih C, Mcrea JC, Seo MH, Oh H, Rhee BG, Mestecky J, Moldoveanu Z, Morgan M, Weitman S. 2001. Biodegradable block copolymers for delivery of proteins and water-insoluble drugs. J Control Release 72:203-215.
203. Sartor O. 2003. Eligard: Leuprolide acetate in a novel sustained-release delivery system. Urology 61:25-31.
204. Hatefi A, Amsden B. 2002. Biodegradable injectable in situ forming drug delivery systems. J Control Release 80:9-28.
205. Matschke C, Isele U, van Hoogevest P, Fahr A. 2002. Sustained-release injectables formed in situ and their potential use for veterinary products. J Control Release 85:1-15.
206. Packhaeuser CB, Schnieders J, Oster CG, Kissel T. 2004. In situ forming parenteral drug delivery systems: An overview. Eur J Pharm Biopharm 58:445-455.
207. Kopacz DJ, Lacouture PG, Wu D, Nandy P, Swanton R, Landau C. 2003. The dose response and effects of dexamethasone on bupivacaine microcapsules for intercostal blockade (T9 to T11) in healthy volunteers. Anesth Analg 96:576-582.
208. Holte K, Werner MU, Lacouture PG, Kehlet H. 2002. Dexamethasone prolongs local analgesia after subcutaneous infiltration of bupivacaine microcapsules in human volunteers. Anesthesiology 96:1331-1335.
209. Heller J, Barr J, Ng S, Shen H-R, Gurny R, Schwach-Abdelaoui K, Rothen-Weinhold A, van de Weert M. 2002. Development of poly(ortho esters) and their application for bovine serum albumin and bupivacaine delivery. J Control Release 78:133-141.
210. Garry MG, Jackson DL, Geier HE, Southam M, Hargreaves KM. 1999. Evaluation of the efficacy of a bioerodible bupivacaine polymer system on antinociception and infammatory mediator release. Pain 82:49-55.
211. Dräger C, Benziger D, Gao F, Berde CB. 1998. Prolonged intercostal nerve blockade in sheep using controlled-release of bupivacaine and dexamethasone from polymer microspheres. Anesthesiology 89:969-979.
212. Castillo J, Curley J, Hotz J, Uezono M, Tigner J, Chasin M, Wilder R, Langer R, Berde C. 1996. Glucocorticoids prolong rat sciatic nerve blockade in vivo from bupivacaine microspheres. Anesthesiology 85:1157-1166.
213. Curley J, Castillo J, Hotz J, Uezono M, Hernandez S, Lim JO, Tigner J, Chasin M, Langer R, Berde C. 1996. Prolonged regional nerve blockade - Injectable biodegradable bupivacaine/polyester microspheres. Anesthesiology 84:1401-1410.
214. Le Corre P, Estèbe JP, Chevanne F, Mallédant Y, Le Verge R. 1995. Spinal controlled delivery of bupivacaine from DL-lactic acid oligomer microspheres. J Pharm Sci 84:75-78.
215. Le Corre P, Le Guevello P, Chevanne F, Le Verge R. 1994. Preparation and characterization of bupivacaine-loaded polylactide and polylactideco-glycolide microspheres. Int J Pharm 107:41-49.
216. Masters DB, Berde CB, Dutta S, Turek T, Langer R. 1993. Sustained local anesthetic release from bioerodible polymer matrices: A potential method for prolonged regional anesthesia. Pharm Res 10:1527-1532.
217. Yu HY, Sun P, Hou WY. 1998. Prolonged local anesthetic effect of bupivacaine liposomes in rats. Int J Pharm 176:133-136.
218. Grant GJ, Lax J, Susser L, Zakowski M, Weissman TE, Turndorf H. 1997. Wound infiltration with liposomal bupivacaine prolongs analgesia in rats. Acta Anaesthesiol Scand 41:204-207.
219. Mowat JJ, Mok MJ, McLeod BA, Madden TD. 1996. Liposomal bupivacaine - Extended duration nerve blockade using large unilamellar vesicles that exhibit a proton gradient. Anesthesiology 85:635-643.
220. Grant GJ, Vermeulen K, Langerman L, Zarkowski M, Turndorf H. 1994. Prolonged analgesia with liposomal bupivacaine in a mouse model. Reg Anesth 19:264-269.
221. Mashimo T, Uchida I, Pak M, Shibata A, Nishimura S, Inagaki Y, Yoshiya I. 1992. Prolongation of canine epidural anesthesia by liposome encapsulation of lidocaine. Anesth Analg 74:827-834.
222. Grant GJ, Barenholz Y, Piskoun B, Bansinath M, Turndorf H, Bolotin EM. 2001. DRV liposomal bupivacaine: Preparation, characterization, and in vivo evaluation in mice. Pharm Res 18:336-343.
223. Grant GJ, Barenholz Y, Bolotin EM, Bansinath M, Turndoft H, Piskoun B, Davidson EM. 2004. A novel liposomal bupivacaine formulation to produce ultralong-acting analgesia. Anesthesiology 101:133-137.
224. Langerman L, Grant GJ, Zakowski M, Golomb E, Ramanathan S, Turndorf H. 1992. Prolongation of epidural anesthesia using a lipid drug carrier with procaine, lidocaine, and tetracaine. Anesth Analg 75:900-905.
225. Langerman L, Grant GJ, Zakowski M, Ramanathan S, Turndorf H. 1992. Prolongation of spinal anesthesia - Differential action of a lipid drug carrier on tetracaine, lidocaine, and procaine. Anesthesiology 77:475-481.
226. Langerman L, Golomb E, Benita S. 1991. Spinal anesthesia: Significant prolongation of the pharmacologic effect of tetracaine with lipid solution of the agent. Anesthesiology 74:105-107.
227. Soderberg L, Dyhre H, Roth B, Bjorkman S. 2006. Ultralong peripheral nerve block by lidocaine: Prilocaine 1:1 mixture in a lipid depot formulation - Comparison of in vitro, in vivo, and effect kinetics. Anesthesiology 104:110-121.
228. Shikanov A, Domb AJ, Weiniger CF. 2007. Long acting local anesthetic-polymer formulation to prolong the effect of analgesia. J Control Release 117:97-103.
229. Kohane DS, Lipp M, Kinney RC, Lotan N, Langer R. 2000. Sciatic nerve blockade with lipid-protein-sugar particles containing bupivacaine. Pharm Res 17:1243-1249.
230. Paavola A, Yliruusi J, Kajimoto Y, Kalso E, Wahlström T, Rosenberg P. 1995. Controlled release of lidocaine from injectable gels and efficacy in rat sciatic nerve block. Pharm Res 12:1997-2002.
231. Dollo G, Le Corre P, Chevanne F, Le Verge R. 2004. Bupivacaine containing dry emulsion can prolong epidural anesthetic effects in rabbits. Eur J Pharm Sci 22:63-70.
232. Masters DB, Domb AJ. 1998. Liposphere local anesthetic timed-release for perineural site application. Pharm Res 15:1038-1045.
233. Hetland ML, Stengaard-Pedersen K, Junker P, Lottenburger T, Ellingsen T, Andersen LS, Hansen I, Skjodt H, Pedersen JK, Lauridsen UB, Svendsen A, Tarp U, Podenphant J, Hansen G, Lindegaard H, de Carvalho A, Østergaard M, Horslev-Petersen K. 2006. Combination treatment with methotrexate, cyclosporine, and intraarticular betamethasone compared with methotrexate and intraarticular betamethasone in early active rheumatoid arthritis - An investigator-initiated, multicenter, randomized, double-blind, parallel-group, placebo-controlled study. Arthritis Rheum 54:1401-1409.
234. Melby JC, St. Cyr M. 1961. Comparative studies on absorption and metabolic disposal of water-soluble corticosteroid esters. Metab Clin Exp 10:75-82.
235. Mollmann H, Rohdewald P, Schmidt EW, Salomon V, Derendorf H. 1985. Pharmacokinetics of triamcinolone acetonide and its phosphate ester. Eur J Clin Pharmacol 29:85-89.
236. Hare LE, Yeh KC, Ditzler CA, Mcmahon FG, Duggan DE. 1975. Bioavailability of dexamethasone. 2. Dexamethasone phosphate. Clin Pharmacol Ther 18:330-337.
237. Derendorf H, Mollmann H, Gruner A, Haack D, Gyselby G. 1986. Pharmacokinetics and pharmacodynamics of glucocorticoid suspensions after intra-articular administration. Clin Pharmacol Ther 39:313-317.
238. Randell TT, Ostman PLG, Flanagan DR, Perng CY, Hrdy J. 1994. Prolonged analgesia after epidural injection of a poorly soluble salt of fentanyl. Anesth Analg 79:905-910.
239. Gido C, Langguth P, Mutschler E. 1994. Predictions of in-vivo plasma-concentrations from in-vitro release kinetics - Application to doxepin parenteral (Im) suspensions in lipophilic vehicles in dogs. Pharm Res 11:800-808.
240. Nakano NI, Kawahara N, Amiya T, Gotoh Y, Furukawa K. 1978. 3-Hydroxy-2-naphthoates of lidocaine, mepivacaine, and bupivacaine and their dissolution characteristics. Chem Pharm Bull 26:936-941.
241. Østergaard J, Larsen SW, Parshad H, Larsen C. 2005. Bupivacaine salts of diflunisal and other aromatic hydroxycarboxylic acids: Aqueous solubility and release characteristics from solutions and suspensions using a rotating dialysis cell model. Eur J Pharm Sci 26:280-287.
242. Larsen SW, Østergaard J, Poulsen SV, Schulz B, Larsen C. 2007. Diflunisal salts of bupivacaine, lidocaine and morphine Use of the common ion effect for prolonging the release of bupivacaine from mixed salt suspensions in an in vitro dialysis model. Eur J Pharm Sci 31:172-179.
243. Zuidema J, Kadir F, Titulaer HAC, Oussoren C. 1994. Release and absorption rates of intramuscularly and subcutaneously injected pharmaceuticals (Ii). Int J Pharm 105:189-207.
244. Chien YM. 1981. Long-acting parenteral drug formulations. J Parenter Sci Technol 35:106-139.
245. Benson HAE, Prankerd RJ. 1998. Optimisation of drug delivery 6. Modified-release parenterals. Aust J Hosp Pharm 28:99-104.
246. Larsen DB, Parshad H, Fredholt K, Larsen C. 2002. Characteristics of drug substances in oily solutions. Drug release rate, partitioning and solubility. Int J Pharm 232:107-117.
247. Larsen SW, Østergaard J, Friberg-Johansen H, Jessen MN, Larsen C. 2006. In vitro assessment of drug release rates from oil depot formulations intended for intra-articular administration. Eur J Pharm Sci 29:348-354.
248. Jorgensen A, Christrup LL, Fullerton A, Christensen CB, Bundgaard H. 1994. Prolonged release from the injection site of morphine from morphine esters in an oil vehicle given by intramuscular injection to pigs. Pharmacol Toxicol 75:319-320.
249. Larsen DB, Fredholt K, Larsen C. 2001. Addition of hydrogen bond donating excipients to oil solution: Effect on in vitro drug release rate and viscosity. Eur J Pharm Sci 13:403-410.
250. Garrood T, Pitzalis C. 2006. Targeting the inflamed synovium: The quest for specificity. Arthritis Rheum 54:1055-1060.
251. Richards PJ, Williams AS, Goodfellow RM, Williams BD. 1999. Liposomal clodronate eliminates synovial macrophages, reduces inflammation and ameliorates joint destruction in antigen-induced arthritis. Rheumatology (Oxford) 38:818-825.
252. Badger AM, Blake S, Kapadia R, Sarkar S, Levin J, Swift BA, Hoffman SJ, Stroup GB, Miller WH, Gowen M, Lark MW. 2001. Disease-modifying activity of SB 273005,an orally active, nonpeptide alpha(v)beta(3) (vitronectin receptor) antagonist, in rat adjuvant-induced arthritis. Arthritis Rheum 44:128-137.
253. Gerlag DM, Borges E, Tak PP, Ellerby HM, Bredesen DE, Pasqualini R, Ruoslahti E, Firestein GS. 2001. Suppression of murine collagen-induced arthritis by targeted apoptosis of synovial neovasculature. Arthritis Res 3:357-361.
254. Koning GA, Schiffelers RM, Wauben MHM, Kok RJ, Mastrobattista E, Molema G, ten Hagen TLM, Storm G. 2006. Targeting of angiogenic endothelial cells at sites of inflammation by dexamethasone phosphate-containing RGD peptide liposomes inhibits experimental arthritis. Arthritis Rheum 54:1198-1208.
255. Pasqualini R, Koivunen E, Kain R, Lahdenranta J, Sakamoto M, Stryhn A, Ashmun RA, Shapiro LH, Arap W, Ruoslahti E. 2000. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res 60:722-727.
256. Mi ZB, Lu XL, Mai JC, Bobby GN, Wang GQ, Lechman ER, Watkins SC, Rabinowich H, Robbins PD. 2003. Identification of a synovial fibroblast-specific protein transduction domain for delivery of apoptotic agents to hyperplastic synovium. Mol Ther 8:295-305.
257. Suzuki YS, Momose Y, Higashi N, Shigematsu A, Park KB, Kim YM, Kim JR, Ryu JR. 1998. Biodistribution and kinetics of holmium-166-chitosan complex (DW-166HC) in rats and mice. J Nucl Med 39:2161-2166.
258. Burgess DJ, Hussain AS, Ingallinera TS, Chen ML. 2002. Assuring quality and performance of sustained and controlled release parenterals: Workshop report. AAPS Pharmsci 4:E7.
259. Burgess DJ, Crommelin DJ, Hussain AS, Chen ML. 2004. Assuring quality and performance of sustained and controlled release parenterals: EUFEPS workshop report. AAPS Pharmsci 6:E11.
260. Burgess DJ, Crommelin DJ, Hussain AS, Chen ML. 2004. Assuring quality and performance of sustained and controlled released parenterals. Eur J Pharm Sci 21:679-690.
261. D'Souza SS, Deluca PP. 2006. Methods to assess in vitro drug release from injectable polymeric particulate systems. Pharm Res 23:460-474.
262. Washington C. 1990. Drug release from microdisperse systems - A critical-review. Int J Pharm 58:1-12.
263. Washington C. 1989. Evaluation of non-sink dialysis methods for the measurement of drug release from colloids - Effects of drug partition. Int J Pharm 56:71-74.
264. D'Souza SS, Deluca PP. 2005. Development of a dialysis in vitro release method for biodegradabl microspheres. AAPS Pharmscitech 6:E323-E328.
265. D'Souza SS, Faraj JA, Deluca PP. 2005. A model-dependent approach to correlate accelerated with real-time release from biodegradable microspheres. AAPS Pharmscitech 6:E553-E564.
266. Gabriels M, Plaizier-Vercammen J. 2003. Physical and chemical evaluation of liposomes, containing artesunate. J Pharm Biomed Anal 31:655-667.
267. Henriksen I, Sande SA, Smistad G, Agren T, Karlsen J. 1995. In-vitro evaluation of drug-release kinetics from liposomes by fractional dialysis. Int J Pharm 119:231-238.
268. Saarinen-Savolainen P, Jarvinen T, Taipale H, Urtti A. 1997. Method for evaluating drug release from liposomes in sink conditions. Int J Pharm 159:27-33.
269. Leo E, Cameroni R, Forni F. 1999. Dynamic dialysis for the drug release evaluation from doxorubicin-gelatin nanoparticle conjugates. Int J Pharm 180:23-30.
270. Chidambaram N, Burgess DJ. 1999. A novel in vitro release method for submicron sized dispersed systems. AAPS Pharmsci 1:E11.
271. Levy MY, Benita S. 1990. Drug release from submicronized o/w emulsion - A new in vitro kinetic evaluation model. Int J Pharm 66:29-37.
272. Kranz H, Bodmeier R. 2007. A novel in situ forming drug delivery system for controlled parenteral drug delivery. Int J Pharm 332:107-114.
273. Itoh S, Teraoka N, Matsuda T, Okamoto K, Takagi T, Oo C, Danny KH. 2006. Reciprocating dialysis tube method: Periodic tapping improved in vitro release/dissolution testing of suppositories. Eur J Pharm Biopharm 64:393-398.
274. Lootvoet G, Beyssac E, Shiu GK, Aiache JM, Ritschel WA. 1992. Study on the release of indomethacin from suppositories - In vitro-in vivo correlation. Int J Pharm 85:113-120.
275. Oribe T, Yamada M, Takeuchi K, Tsunemi S, Imasaka K, Shirakura O, Ishimaru S, Takayama K, Nagai T. 1995. Formulation and in-vivo in-vitro correlation of the dissolution property of lemildipine solid dispersions-incorporated suppositories. Int J Pharm 124:27-35.
276. Pedersen BT, Østergaard J, Larsen SW, Larsen C. 2005. Characterization of the rotating dialysis cell as an in vitro model potentially useful for simulation of the pharmacokinetic fate of intraarticularly administered drugs. Eur J Pharm Sci 25:73-79.
277. Fredholt K, Larsen DH, Larsen C. 2000. Modification of in vitro drug release rate from oily parenteral depots using a formulation approach. Eur J Pharm Sci 11:231-237.
278. Larsen DH, Fredholt K, Larsen C. 2000. Assessment of rate of drug release from oil vehicle using a rotating dialysis cell. Eur J Pharm Sci 11:223-229.
279. Schultz K, Mollgaard B, Frokjaer S, Larsen C. 1997. Rotating dialysis cell as in vitro release method for oily parenteral depot solutions. Int J Pharm 157:163-169.
280. Simmons DL. 2006. What makes a good antiinflammatory drug target? Drug Discov Today 11:210-219.
281. Malemud CJ. 2004. Cytokines as therapeutic targets for osteoarthritis. Biodrugs 18:23-35.
282. Connell L, McInnes IB. 2006. New cytokine targetsin inflammatory rheumatic diseases. Best Pract Res Clin Rheumatol 20:865-878.
283. Fernandes JC, Martel-Pelletier J, Pelletier JP. 2002. The role of cytokines in osteoarthritis pathophysiology. Biorheology 39:237-246.
284. Glasson SS, Askew R, Sheppard B, Carito B, Blanchet T, Ma HL, Flannery CR, Peluso D, Kanki K, Yang ZY, Majumdar MK, Morris EA. 2005. Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis. Nature 434:644-648.
285. Stanton H, Rogerson FM, East CJ, Golub SB, Lawlor KE, Meeker CT, Little CB, Last K, Farmer PJ, Campbell IK, Fourie AM, Fosang AJ. 2005. ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro. Nature 434:648-652.
286. Komatsu S, Iwata H, Nabeshima T. 1999. Studies on the kinetics, metabolism and re-utilisation after intra-articular administration of hyaluronan to rabbits. Arzneimittelforschung 49:427-433.
287. Wintzer HJ, Fitzek A, Frey HH. 1981. Pharmacokinetics of procaine injected into the hock joint of the horse. Equine Vet J 13:68-69.
288. Lindqvist U, Tolmachev V, Kairemo K, Astrom G, Jonsson E, Lundqvist H. 2002. Elimination of stabilised hyaluronan from the knee joint in healthy men. Clin Pharmacokinet 41:603-613.
289. Biswas NR, Mandal NG, PGL LK. 1995. Pharmacokinetic profile of intra-articular lignocaine during knee joint arthroscopy. Indian J Pharmacol 27:193-194.
290. Kay EA, Klimiuk PS, Ronson G, Bailie GR. 1988. Failure of intraarticular ceftazidime in a patient with Pseudomonas aeruginosa septic arthritis. Drug Intell Clin Pharm 22:315-316.
291. Elmquist WF, Chan KKH, Sawchuk RJ. 1994. Transsynovial drug distribution: Synovial mean transit time of diclofenac and other nonsteroidal antiinflammatory drugs. Pharm Res 11:1689-1697.
292. Day RO, Williams KM, Graham GG, Lee EJ, Knihinicki RD, Champion GD. 1988. Stereoselective disposition of ibuprofen enantiomers in synovial fluid. Clin Pharmacol Ther 43:480-487.
293. Williams AS, Camilleri JP, Goodfellow RM, Williams BD. 1996. A single intra-articular injection of liposomally conjugated methotrexate suppresses joint inflammation in rat antigen-induced arthritis. Br J Rheumatol 35:719-724.
294. Abe T, Yamada H, Nakajima H, Kikuchi T, Takaishi H, Tadakuma T, Fujikawa K, Toyama Y. 2003. Repair of full-thickness cartilage defects using liposomal transforming growth factor-beta1. J Orthop Sci 8:92-101.
295. Trif M, Guillen C, Vaughan DM, Telfer JM, Brewer JM, Roseanu A, Brock JH. 2001. Liposomes as possible carriers for lactoferrin in the local treatment of inflammatory diseases. Exp Biol Med (Maywood) 226:559-564.
296. Highton J, Guevremont D, Thomson J, Carlisle B, Tucker I. 1999. A trial of clodronate-liposomes as anti-macrophage treatment in a sheep model of arthritis. Clin Exp Rheumatol 17:43-48.
297. van Lent PL, van den BL, van den Hoek AE, van de EM, Dijkstra CD, Van RN, Van de Putte LB, van den Berg WB. 1993. Reversible depletion of synovial lining cells after intra-articular treatment with liposome-encapsulated dichloromethylene diphosphonate. Rheumatol Int 13:21-30.
298. van Lent PL, Holthuysen AE, Van RN, Van de Putte LB, van den Berg WB. 1998. Local removal of phagocytic synovial lining cells by clodronateliposomes decreases cartilage destruction during collagen type II arthritis. Ann Rheum Dis 57:408-413.
299. Ceponis A, Waris E, Monkkonen J, Laasonen L, Hyttinen M, Solovieva SA, Hanemaaijer R, Bitsch A, Konttinen YT. 2001. Effects of low-dose, noncytotoxic, intraarticular liposomal clodronate on development of erosions and proteoglycan loss in established antigen-induced arthritis in rabbits. Arthritis Rheum 44:1908-1916.
300. Barrera P, Blom A, van Lent PL, van BL, Beijnen JH, Van RN, de Waal Malefijt MC, Van de Putte LB, Storm G, van den Berg WB. 2000. Synovial macrophage depletion with clodronate-containing liposomes in rheumatoid arthritis. Arthritis Rheum 43:1951-1959.
301. Bard DR, Knight CG, Page Thomas DP. 1983. The retention and distribution in the rabbit knee of a radionuclide complexed with a lipophilic chelator in liposomes. Clin Exp Rheumatol 1:113-117.
302. Chowdhary RK, Ratkay LG, Canaan AJ, Waterfield JD, Richter AM, Levy JG. 1998. Uptake of verteporfin by articular tissues following systemic and intra-articular administration. Biopharm Drug Dispos 19:395-400.
303. Ratcliffe JH, Hunneyball IM, Smith A, Wilson CG, Davis SS. 1984. Preparation and evaluation of biodegradable polymeric systems for the intraarticular delivery of drugs. J Pharm Pharmacol 36:431-436.
304. Ratcliffe JH, Hunneyball IM, Wilson CG, Smith A, Davis SS. 1987. Albumin microspheres for intraarticular drug delivery: Investigation of their retention in normal and arthritic knee joints of rabbits. J Pharm Pharmacol 39:290-295.
305. Burgess DJ, Davis SS. 1988. Potential use of albumin microspheres as a drug delivery system. 2. In vivo deposition and release of steroids. Int J Pharm 46:69-76.
306. Tuncay M, Calis S, Kas HS, Ercan MT, Peksoy I, Hincal AA. 2000. In vitro and in vivo evaluation of diclofenac sodium loaded albumin microspheres. J Microencapsul 17:145-155.
307. Tuncay M, Calis S, Kas HS, Ercan MT, Peksoy I, Hincal AA. 2000. Diclofenac sodium incorporated PLGA (50:50) microspheres: Formulation considerations and in vitro/in vivo evaluation. Int J Pharm 195:179-188.
308. Thakkar H, Sharma RK, Mishra AK, Chuttani K, Murthy RS. 2004. Efficacy of chitosan microspheres for controlled intra-articular delivery of celecoxib in inflamed joints. J Pharm Pharmacol 56:1091-1099.
309. Thakkar H, Sharma RK, Mishra AK, Chuttani K, Murthy RS. 2004. Celecoxib incorporated chitosan microspheres: In vitro and in vivo evaluation. J Drug Target 12:549-557.
310. Bozdag S, Calis S, Kas HS, Ercan MT, Peksoy I, Hincal AA. 2001. In vitro evaluation and intra-articular administration of biodegradable microspheres containing naproxen sodium. J Microencapsul 18:443-456.
311. Ramesh DV, Tabata Y, Ikada Y. 1999. Bioabsorbable microspheres for local drug release in the articulus. J Bioact Compat Polym 14:137-149.
312. Nishide M, Kamei S, Takakura Y, Tamai S, Tabata Y, Ikada Y. 1999. Fate of biodegradable DL-lactic acid oligomer microspheres in the articulus. J Bioact Compat Polym 14:385-398.
313. Liggins RT, Cruz T, Min W, Liang L, Hunter WL, Burt HM. 2004. Intra-articular treatment of arthritis with microsphere formulations of paclitaxel: Biocompatibility and efficacy determinations in rabbits. Inflamm Res 53:363-372.
314. Horisawa E, Kubota K, Tuboi I, Sato K, Yamamoto H, Takeuchi H, Kawashima Y. 2002. Size-dependency of DL-lactide/glycolide copolymer particulates for intra-articular delivery system on phagocytosis in rat synovium. Pharm Res 19:132-139.
315. Horisawa E, Hirota T, Kawazoe S, Yamada J, Yamamoto H, Takeuchi H, Kawashima Y. 2002. Prolonged anti-inflammatory action of DL-lactide/glycolide copolymer nanospheres containing beta-methasone sodium phosphate for an intra-articular delivery system in antigen-induced arthritic rabbit. Pharm Res 19:403-410.
316. Liang LS, Jackson J, Min W, Risovic V, Wasan KM, Burt HM. 2004. Methotrexate loaded poly(L-lactic acid) microspheres for intra-articular delivery of methotrexate to the joint. J Pharm Sci 93:943-956.
317. Liang LS, Wong W, Burt HM. 2005. Pharmacokinetic study of methotrexate following intraarticular injection of methotrexate loaded poly(L-lactic acid) microspheres in rabbits. J Pharm Sci 94:1204-1215.
318. Cai L, Okumu FW, Cleland JL, Beresini M, Hogue D, Lin Z, Filvaroff EH. 2002. A slow release formulation of insulin as a treatment for osteoarthritis. Osteoarthr Cartil 10:692-706.
319. Mumper RJ, Mills BJ, Ryo UY, Jay M. 1992. Polymeric microspheres for radionuclide synovectomy containing neutron-activated holmium-166. J Nucl Med 33:398-402.
320. Song J, Suh CH, Park YB, Lee SH, Yoo NC, Lee JD, Kim KH, Lee SK. 2001. A phase I/IIa study on intra-articular injection of holmium-166-chitosan complex for the treatment of knee synovitis of rheumatoid arthritis. Eur J Nucl Med 28:489-497.
321. Lee SH, Suh JS, Kim HS, Lee JD, Song J, Lee SK. 2003. MR evaluation of radiation synovectomy of the knee by means of intra-articular injection of holmium-166-chitosan complex in patients with rheumatoid arthritis: Results at 4-month followup. Korean J Radiol 4:170-178.
322. Schulze K, Koch A, Schopf B, Petri A, Steitz B, Chastellain M, Hofmann M, Hofmann H, Von Rechenberg B. 2005. Intraarticular application of superparamagnetic nanoparticles and their uptake by synovial membrane - An experimental study in sheep. J Magnetism Magn Mater 293:419-432.
323. Ohlsson-Wilhelm BM, McDevitt MR, Gray BD, Lorinc R, McIlvain HB, Sheth K, Weeks SA, Muirhead KA. 1994. Zyn-Linker delivery of antirheumatic agents. Immunol Res 13:82-95.
324. Rahmouni A, Mathieu D, Chambon C, Dao TH, Hernigou P, Vasile N. 1995. Intraarticular tolerability and kinetics of gadolinium tetra-azacyclododecane tetraacetic acid. Acad Radiol 2:413-417.
325. Mierisch CM, Cohen SB, Jordan LC, Robertson PG, Balian G, Diduch DR. 2002. Transforming growth factor-beta in calcium alginate beads for the treatment of articular cartilage defects in the rabbit. Arthroscopy 18:892-900.
326. Inoue A, Takahashi KA, Arai Y, Tonomura H, Sakao K, Saito M, Fujioka M, Fujiwara H, Tabata Y, Kubo T. 2006. The therapeutic effects of basic fibroblast growth factor contained in gelatin hydrogel microspheres on experimental osteoarthritis in the rabbit knee. Arthritis Rheum 54:264-270.
327. Senda H, Sakuma E, Wada I, Wang HJ, Maruyama H, Matsui N. 1999. Ultrastructural study of cells at the synovium-cartilage junction: Response of synovial cells of the rat knee joint to intra-articularly injected latex particles. Kaibogaku Zasshi 74:525-535.